Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 4 Interventional Results available

Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409

ClinicalTrials.gov ID: NCT02255656

Public ClinicalTrials.gov record NCT02255656. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 1:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Long-term Follow-up Study for Multiple Sclerosis Patients Who Have Completed the Alemtuzumab Extension Study (CAMMS03409)

Study identification

NCT ID
NCT02255656
Recruitment status
Completed
Study type
Interventional
Phase
Phase 4
Lead sponsor
Genzyme, a Sanofi Company
Industry
Enrollment
1,062 participants

Conditions and interventions

Interventions

  • alemtuzumab GZ402673 Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 6, 2015
Primary completion
Jul 14, 2020
Completion
Jul 14, 2020
Last update posted
Mar 27, 2022

2015 – 2020

United States locations

U.S. sites
52
U.S. states
25
U.S. cities
50
Facility City State ZIP Site status
Investigational Site Number 1086 Cullman Alabama 00000
Investigational Site Number 1031 Phoenix Arizona 85013
Investigational Site Number 1171 Phoenix Arizona 85018
Investigational Site Number 1090 Tucson Arizona 85704
Investigational Site Number 1040 Berkeley California 94705
Investigational Site Number 1152 Fullerton California 92835
Investigational Site Number 1093 Pasadena California 91105
Investigational Site Number 1027 Fort Collins Colorado 80528
Investigational Site Number 1078 Jacksonville Florida 32209
Investigational Site Number 1059 Maitland Florida 32751
Investigational Site Number 1173 Sarasota Florida 34239
Investigational Site Number 1034 Sunrise Florida 33351
Investigational Site Number 1005 Tampa Florida 33609
Investigational Site Number 1049 Tampa Florida 33612
Investigational Site Number 1008 Northbrook Illinois 60062
Investigational Site Number 1001 Fort Wayne Indiana 46845
Investigational Site Number 1024 Indianapolis Indiana 46202
Investigational Site Number 1017 Des Moines Iowa 50314
Investigational Site Number 1022 Kansas City Kansas 66160
Investigational Site Number 1083 Lenexa Kansas 66214
Investigational Site Number 1039 Lexington Kentucky 40513
Investigational Site Number 1021 Louisville Kentucky 40202
Investigational Site Number 1061 Wellesley Massachusetts 02481
Investigational Site Number 1028 Worcester Massachusetts 01655
Investigational Site Number 1025 Ann Arbor Michigan 48105-2945
Investigational Site Number 1020 Detroit Michigan 48201
Investigational Site Number 1054 Traverse City Michigan 49684
Investigational Site Number 1084 Kansas City Missouri 64111
Investigational Site Number 1092 St Louis Missouri 63131
Investigational Site Number 1073 Teaneck New Jersey 07666
Investigational Site Number 1014 Albuquerque New Mexico 87131
Investigational Site Number 1081 Mineola New York 11501
Investigational Site Number 1026 New York New York 10029
Investigational Site Number 1160 Patchogue New York 11772
Investigational Site Number 1015 Rochester New York 14642
Investigational Site Number 1053 Syracuse New York 13202
Investigational Site Number 1095 Chapel Hill North Carolina 27599
Investigational Site Number 1082 Winston-Salem North Carolina 27103
Investigational Site Number 1035 Cleveland Ohio 44195
Investigational Site Number 1058 Uniontown Ohio 44685
Investigational Site Number 1067 Oklahoma City Oklahoma 73104
Investigational Site Number 1097 Allentown Pennsylvania 18103
Investigational Site Number 1057 Providence Rhode Island 02905
Investigational Site Number 1163 Cordova Tennessee 38018
Investigational Site Number 1055 Franklin Tennessee 37064
Investigational Site Number 1009 Knoxville Tennessee 37922
Investigational Site Number 1042 Nashville Tennessee 37215
Investigational Site Number 1018 Houston Texas 77030
Investigational Site Number 1002 Round Rock Texas 78681
Investigational Site Number 1046 San Antonio Texas
Investigational Site Number 1037 Vienna Virginia 22182
Investigational Site Number 1068 Seattle Washington 98122

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 79 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02255656, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 27, 2022 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02255656 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →